This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacDonald, K S Articles by Ronald, A R Search for Related Content PubMed PubMed Citation Articles by MacDonald, K S Articles by Ronald, A R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 May; 33(5): 612-614

Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.

K S MacDonald, D W Cameron, L D'Costa, J O Ndinya-Achola, F A Plummer and A R Ronald

Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.

ABSTRACT

Chancroid is gaining importance as a sexually transmitted disease because of its association with transmission of human immunodeficiency virus type 1 (HIV-1). Effective, simply administered therapy for chancroid is necessary. Fleroxacin is effective against Haemophilus ducreyi in vitro. We performed an initial randomized clinical trial to assess the efficacy of fleroxacin for treatment of chancroid in Nairobi, Kenya. Fifty-three men with culture-positive chancroid were randomly assigned to receive either 200 mg (group 1) or 400 mg (group 2) of fleroxacin as a single oral dose. Groups 1 and 2 were similar with regard to severity of disease, bubo formation, and HIV-1 status. A satisfactory clinical response to therapy was noted in 23 of 26 patients (88%) in group 1 and 18 of 23 patients (78%) in group 2. Bacteriological failure occurred in 1 of 26 evaluable patients (4%) in group 1 and 4 of 23 evaluable patients (17%) in group 2. Two of 37 HIV-1-seronegative men (5%) and 3 of 11 HIV-1-infected men (27%) were bacteriological failures. Fleroxacin, 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.

---

Antimicrob Agents Chemother. 1989 May; 33(5): 612-614

This article has been cited by other articles:

• Roy-Leon, J. E., Lauzon, W. D., Toye, B., Singhal, N., Cameron, D. W. (2005). In vitro and in vivo activity of combination antimicrobial agents on Haemophilus ducreyi. J Antimicrob Chemother 56: 552-558 [Abstract] [Full Text]  
• Lewis, D A (2003). Chancroid: clinical manifestations, diagnosis, and management. Sex. Transm. Infect. 79: 68-71 [Abstract] [Full Text]  
• Lewis, D. A (2000). Diagnostic tests for chancroid. Sex. Transm. Infect. 76: 137-141 [Full Text]  
• Minkoff, H. L., DeHovitz, J. A. (1991). Care of Women Infected With the Human Immunodeficiency Virus. JAMA 266: 2253-2258 [Abstract]